Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Diseases

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 34 articles:
HTML format



Single Articles


    July 2021
  1. KELLEY RK, Sangro B, Harris W, Ikeda M, et al
    Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
    J Clin Oncol. 2021 Jul 22:JCO2003555. doi: 10.1200/JCO.20.03555.
    PubMed     Abstract available


    June 2021
  2. QIN S, Bi F, Gu S, Bai Y, et al
    Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
    J Clin Oncol. 2021 Jun 29:JCO2100163. doi: 10.1200/JCO.21.00163.
    PubMed     Abstract available


    November 2020
  3. GORDAN JD, Kennedy EB, Abou-Alfa GK, Beg MS, et al
    Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
    J Clin Oncol. 2020 Nov 16:JCO2002672. doi: 10.1200/JCO.20.02672.
    PubMed     Abstract available


    September 2020
  4. TANG W, Ren L, Liu T, Ye Q, et al
    Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.
    J Clin Oncol. 2020;38:3175-3184.
    PubMed     Abstract available


  5. CHAO C, Bhatia S, Xu L, Cannavale KL, et al
    Chronic Comorbidities Among Survivors of Adolescent and Young Adult Cancer.
    J Clin Oncol. 2020;38:3161-3174.
    PubMed     Abstract available


    July 2020
  6. FINN RS, Ikeda M, Zhu AX, Sung MW, et al
    Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
    J Clin Oncol. 2020 Jul 27:JCO2000808. doi: 10.1200/JCO.20.00808.
    PubMed     Abstract available


    May 2020
  7. HIYAMA E, Hishiki T, Watanabe K, Ida K, et al
    Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol.
    J Clin Oncol. 2020 May 18:JCO1901067. doi: 10.1200/JCO.19.01067.
    PubMed     Abstract available


  8. LEVY EB, Fiel MI, Hamilton SR, Kleiner DE, et al
    State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach.
    J Clin Oncol. 2020;38:1633-1640.
    PubMed     Abstract available


    December 2019
  9. FINN RS, Ryoo BY, Merle P, Kudo M, et al
    Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
    J Clin Oncol. 2019 Dec 2:JCO1901307. doi: 10.1200/JCO.19.01307.
    PubMed     Abstract available


    October 2019
  10. MODEST DP, Martens UM, Riera-Knorrenschild J, Greeve J, et al
    FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
    J Clin Oncol. 2019 Oct 14:JCO1901340. doi: 10.1200/JCO.19.01340.
    PubMed     Abstract available


    July 2019
  11. WEI X, Jiang Y, Zhang X, Feng S, et al
    Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.
    J Clin Oncol. 2019 Jul 8:JCO1802184. doi: 10.1200/JCO.18.02184.
    PubMed     Abstract available


    January 2019
  12. TWIST CJ, Naranjo A, Schmidt ML, Tenney SC, et al
    Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.
    J Clin Oncol. 2019;37:115-124.
    PubMed     Abstract available


    December 2018
  13. PINATO DJ, Allara E, Chen TY, Trevisani F, et al
    Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study.
    J Clin Oncol. 2018 Dec 18:JCO1800885. doi: 10.1200/JCO.18.00885.
    PubMed     Abstract available


    June 2018
  14. SHINDE A, Jones BL, Chen YJ, Amini A, et al
    Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma: Does Radiation Dose Make a Difference?
    J Clin Oncol. 2018 Jun 26:JCO2018786012. doi: 10.1200/JCO.2018.78.6012.
    PubMed    


  15. FIORENTINO A, Alongi F
    Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: No Way Out Without a Randomized Trial?
    J Clin Oncol. 2018 Jun 26:JCO2018781005. doi: 10.1200/JCO.2018.78.1005.
    PubMed    


  16. OHRI N, Kabarriti R, Kaubisch A, Guha C, et al
    Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: Caution When Interpreting Observational Data.
    J Clin Oncol. 2018 Jun 26:JCO2018780122. doi: 10.1200/JCO.2018.78.0122.
    PubMed    


  17. WAHL DR, Schipper MJ, Parikh ND, Owen D, et al
    Casual Causality: Does Radiofrequency Ablation Really Prolong Survival After Treatment of Localized Hepatocellular Carcinoma?
    J Clin Oncol. 2018 Jun 26:JCO2018780882. doi: 10.1200/JCO.2018.78.0882.
    PubMed    


  18. KIM N, Seong J
    What Role Does Locally Ablative Stereotactic Body Radiotherapy Play Versus Radiofrequency Ablation in Localized Hepatocellular Carcinoma?
    J Clin Oncol. 2018 Jun 26:JCO2018781740. doi: 10.1200/JCO.2018.78.1740.
    PubMed    


  19. SANUKI N, Takeda A
    Are Head-to-Head Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy Really Necessary for Localized Hepatocellular Carcinoma?
    J Clin Oncol. 2018 Jun 26:JCO2018782805. doi: 10.1200/JCO.2018.78.2805.
    PubMed    


  20. OLSEN JR, Murphy JD, Hallemeier CL, Apisarnthanarax S, et al
    Cross-Modality Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy for Treatment of Hepatocellular Carcinoma: Limitations of the National Cancer Database.
    J Clin Oncol. 2018 Jun 26:JCO2018782904. doi: 10.1200/JCO.2018.78.2904.
    PubMed    


  21. SMITH GL, Das P, Herman JM, Koay EJ, et al
    Comparing Ablative Modalities for Hepatocellular Carcinoma: Cautions in Interpreting Big Data.
    J Clin Oncol. 2018 Jun 26:JCO2018785428. doi: 10.1200/JCO.2018.78.5428.
    PubMed    


    May 2018
  22. RIAZ A, Lewandowski R, Salem R
    Radioembolization in Advanced Hepatocellular Carcinoma.
    J Clin Oncol. 2018 May 2:JCO2018777227. doi: 10.1200/JCO.2018.77.7227.
    PubMed     Abstract available


    March 2018
  23. CHOW PKH, Gandhi M, Tan SB, Khin MW, et al
    SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.
    J Clin Oncol. 2018 Mar 2:JCO2017760892. doi: 10.1200/JCO.2017.76.0892.
    PubMed     Abstract available


    January 2018
  24. RAJYAGURU DJ, Borgert AJ, Smith AL, Thomes RM, et al
    Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
    J Clin Oncol. 2018 Jan 12:JCO2017753228. doi: 10.1200/JCO.2017.75.3228.
    PubMed     Abstract available


    September 2017
  25. O'NEILL AF, Towbin AJ, Krailo MD, Xia C, et al
    Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
    J Clin Oncol. 2017 Sep 11:JCO2017735654. doi: 10.1200/JCO.2017.73.5654.
    PubMed     Abstract available


  26. REISS KA, Yu S, Mamtani R, Mehta R, et al
    Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.
    J Clin Oncol. 2017 Sep 5:JCO2017738245. doi: 10.1200/JCO.2017.73.8245.
    PubMed     Abstract available


    August 2017
  27. IKOMA N, You YN, Bednarski BK, Rodriguez-Bigas MA, et al
    Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.
    J Clin Oncol. 2017;35:2631-2638.
    PubMed     Abstract available


    May 2017
  28. PERSONENI N, Rimassa L, Giordano L, Santoro A, et al
    Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater!
    J Clin Oncol. 2017 May 4:JCO2017727776. doi: 10.1200/JCO.2017.72.7776.
    PubMed    


    April 2017
  29. GROOT KOERKAMP B, Sadot E, Kemeny NE, Gonen M, et al
    Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis.
    J Clin Oncol. 2017 Apr 20:JCO2016718346. doi: 10.1200/JCO.2016.71.8346.
    PubMed     Abstract available


  30. BRAILLON A
    Recurrence in Early-Stage Hepatocellular Carcinoma: CpG Methylation and Smoking.
    J Clin Oncol. 2017 Apr 11:JCO2017723932. doi: 10.1200/JCO.2017.72.3932.
    PubMed    


  31. PAGLIARO LC
    Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors.
    J Clin Oncol. 2017;35:1036-1040.
    PubMed     Abstract available


    January 2017
  32. FERRAROTTO R, Mitani Y, Diao L, Guijarro I, et al
    Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
    J Clin Oncol. 2017;35:352-360.
    PubMed     Abstract available


    December 2016
  33. NAGTEGAAL ID, Knijn N, Hugen N, Marshall HC, et al
    Tumor Deposits in Colorectal Cancer: Improving the Value of Modern Staging-A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2016 Dec 28:JCO2016689091.
    PubMed     Abstract available


    March 2016
  34. HALABI S, Kelly WK, Ma H, Zhou H, et al
    Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2016 Mar 7. pii: JCO657270.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: